ECSP056039A - PERORAL PHARMACEUTICAL FORMULATION FOR PROTECTION PUMP ANTAGONIST AGENTS - Google Patents
PERORAL PHARMACEUTICAL FORMULATION FOR PROTECTION PUMP ANTAGONIST AGENTSInfo
- Publication number
- ECSP056039A ECSP056039A EC2005006039A ECSP056039A ECSP056039A EC SP056039 A ECSP056039 A EC SP056039A EC 2005006039 A EC2005006039 A EC 2005006039A EC SP056039 A ECSP056039 A EC SP056039A EC SP056039 A ECSP056039 A EC SP056039A
- Authority
- EC
- Ecuador
- Prior art keywords
- pharmaceutical formulation
- antagonist agents
- pump antagonist
- protection pump
- peroral pharmaceutical
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 abstract 1
- 108010083204 Proton Pumps Proteins 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
El invento se refiere a nuevas formas de dosificación para agentes antagonistas de bombas de protones.The invention relates to new dosage forms for proton pump antagonist agents.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10317023A DE10317023A1 (en) | 2003-04-11 | 2003-04-11 | Oral dosage form useful in the treatment and prevention of gastrointestinal disorders e.g. inflammatory disorders and lesions such as gastric ulcer comprises proton pump inhibitor and basic excipients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP056039A true ECSP056039A (en) | 2006-01-27 |
Family
ID=33154195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2005006039A ECSP056039A (en) | 2003-04-11 | 2005-09-26 | PERORAL PHARMACEUTICAL FORMULATION FOR PROTECTION PUMP ANTAGONIST AGENTS |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN1767817A (en) |
| DE (1) | DE10317023A1 (en) |
| EC (1) | ECSP056039A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10835541B2 (en) | 2015-07-30 | 2020-11-17 | Takeda Pharmaceutical Company Limited | Tablet |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104027344B (en) * | 2014-06-20 | 2016-08-24 | 新乡医学院 | Comprise the pharmaceutical composition of lincomycin |
| CN111184867A (en) * | 2020-03-19 | 2020-05-22 | 龚跃明 | Chemical medicine composition for treating helicobacter pylori infection |
-
2003
- 2003-04-11 DE DE10317023A patent/DE10317023A1/en not_active Ceased
-
2004
- 2004-04-08 CN CNA2004800087404A patent/CN1767817A/en active Pending
-
2005
- 2005-09-26 EC EC2005006039A patent/ECSP056039A/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10835541B2 (en) | 2015-07-30 | 2020-11-17 | Takeda Pharmaceutical Company Limited | Tablet |
Also Published As
| Publication number | Publication date |
|---|---|
| DE10317023A1 (en) | 2004-11-11 |
| CN1767817A (en) | 2006-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120377T1 (en) | SOLID PHARMACEUTICAL DOSAGE PHARMACEUTICAL FORM CONTAINING LOPINAVIR | |
| AR095848A2 (en) | IMIDAZOLIC DERIVATIVES OF PROPIONAMIDE MODULATORS OF OPIOID RECEPTORS | |
| BRPI0417717A (en) | compound, pharmaceutical composition, and use of a compound | |
| DK1521573T3 (en) | Non-polymeric, lipophilic, pharmaceutical implant compositions for intracellular use | |
| CL2008000418A1 (en) | Use of an il-23 antagonist for the treatment of a fungal infection. | |
| BRPI0606339A2 (en) | alcohol resistant dosage forms | |
| UY29562A1 (en) | AMINO BENZOIL HETEROCYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCEDURES AND APPLICATIONS | |
| NO20052739D0 (en) | CCR5 antagonists as drugs | |
| CR9772A (en) | ISOINDOL-IMIDA COMPOUNDS AND COMPOSITIONS THAT INCLUDE IT AND METHODS TO USE THE SAME | |
| CO6362017A2 (en) | THERAPEUTIC ANTIVIRAL PEPTIDES | |
| MXPA05012463A (en) | Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility. | |
| BRPI0815894A2 (en) | PHARMACEUTICAL COMPOSITION, USE OF THE SAME, AND PHARMACEUTICALLY ACCEPTABLE SALTS OF A COMPOUND. | |
| NO20080219L (en) | Fentanyl formulation containing an essential oil | |
| NO20063393L (en) | Pharmaceutical preparations | |
| EA200600953A1 (en) | DOSED FORMS OF TORECEMIDA OF PROLONGED DELIVERY | |
| DK1814848T3 (en) | 2,3,4-substituted-cyclopentanones as therapeutic agents | |
| BRPI0417265A (en) | pharmaceutical composition comprising an active ingredient and sulfobetaine | |
| NO20055207L (en) | Oral pharmaceutical preparation for proton pump antagonists | |
| EP1900368A4 (en) | TABLET CONTAINING AN ACTIVE SOLUBLE INGREDIENT | |
| ECSP056039A (en) | PERORAL PHARMACEUTICAL FORMULATION FOR PROTECTION PUMP ANTAGONIST AGENTS | |
| NO20063293L (en) | Pharmaceutical compounds | |
| ITMI20050477A1 (en) | TRANSDERMIC PATCH | |
| EA200901387A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING DESLORATADINE | |
| DK1420789T3 (en) | Use of active substances with myopioid receptor agonist and opioid receptor antagonist effect as combination drugs for cancer treatment | |
| ATE529432T1 (en) | AZAZYKLOSTEROID AS A LIGAND OF THE HISTAMINE-3 RECEPTORS |